TBPH - Theravance Biopharma Inc
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.50
DETAILS
HIGH:
$17.00
LOW:
$14.00
MEDIAN:
$15.50
CONSENSUS:
$15.50
DOWNSIDE:
8.80%
About Theravance Biopharma Inc (https://www.theravance.com)
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rick E. Winningham | Chief Executive Officer & Director | 1960 | $1,472,019 USD |
| Aine Miller | Senior Vice President of Development & Head of Ireland Office | 1977 | $747,322 USD |
| Brett A. Grimaud | Senior Vice President, General Counsel & Secretary | 1974 | $690,870 USD |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial & Medical Affairs | 1965 | $682,942 USD |
| Aziz Sawaf | Senior Vice President & Chief Financial Officer | 1982 | $660,152 USD |
| Stacy L. Pryce | Senior Vice President & Chief Strategy Officer | – | – |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer | – | – |